Skip to main content

What the FDA labels say about taking them together

Deferasirox and selexipag

Selexipag's FDA label of May 28, 2026 names deferasirox in its drug interactions section; the deferasirox labels PlainMeds reads (3) do not name selexipag. The selexipag label: “DRUG INTERACTIONS Moderate CYP2C8 inhibitors increase exposure to the active metabolite of UPTRAVI.”

Check it at the source: the deferasirox FDA label on DailyMed (effective January 28, 2026, Novartis Pharmaceuticals Corporation); the selexipag FDA label on DailyMed (effective May 28, 2026, Actelion Pharmaceuticals US, Inc.).

What does the deferasirox label say about selexipag?

Deferasirox's label (effective January 28, 2026) and its 2 other brand-application labels do not name selexipag in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Exjade), Novartis Pharmaceuticals Corporation, effective January 28, 2026 (SPL set 3495a70c-870c-4968-940e-8baea152cf85), via openFDA; the full label on DailyMed

What does the selexipag label say about deferasirox?

Selexipag label, drug interactions

DRUG INTERACTIONS Moderate CYP2C8 inhibitors (e.g., clopidogrel, deferasirox and teriflunomide) increase exposure to the active metabolite of UPTRAVI.

Source: FDA drug label (UPTRAVI), Actelion Pharmaceuticals US, Inc., effective May 28, 2026 (SPL set a7a23b87-f892-4e2c-8e2e-ebf841220f90), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

20Deferasirox generic labelers
2Selexipag generic labelers
DeferasiroxSelexipag
Labeled forn/aPulmonary arterial hypertension
Boxed warningYesNo
Pharmacy cost (NADAC)$1.25 per tablet 360 mg tabletn/a
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?